{"nctId":"NCT03142451","briefTitle":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","startDateStruct":{"date":"2017-06-02","type":"ACTUAL"},"conditions":["Facial Papulopustular Rosacea"],"count":751,"armGroups":[{"label":"FMX103 1.5%","type":"EXPERIMENTAL","interventionNames":["Drug: FMX103 minocycline foam 1.5%"]},{"label":"Vehicle foam","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle foam"]}],"interventions":[{"name":"FMX103 minocycline foam 1.5%","otherNames":[]},{"name":"Vehicle foam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Moderate-to-severe rosacea (as per the IGA score) on the proposed facial treatment area consisting of:\n\n   1. At least 15 and not more than 75 facial papules and pustules, excluding lesions involving the eyes and scalp;\n   2. No more than 2 nodules on the face.\n2. Presence of or history of erythema and/or flushing on the face.\n\nExclusion Criteria:\n\n1. Presence of any skin condition and/or Excessive facial hair, on the face that would interfere with the diagnosis or assessment of rosacea.\n2. Moderate or severe rhinophyma, dense telangiectasia (score 3, severe), or plaque-like facial edema.\n3. History of hypersensitivity or allergy to minocycline, any other tetracycline, or of any other component of the formulation.\n4. Active ocular rosacea (eg, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. Lesion counts included the number of papules, pustules, and nodules.\n\nChange from Baseline was calculated as the value at Baseline minus the post-Baseline value. Thus, a positive change reflects a reduction in lesion count.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.56","spread":"0.442"},{"groupId":"OG001","value":"15.34","spread":"0.604"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Investigator Global Assessments (IGA) Treatment Success at Week 12","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. The Investigator assessed the global severity of rosacea using the IGA scale. The scale ranges from 0 (Clear): No inflammatory papules or pustules to 4 (Severe): Many inflammatory papules or pustules, and up to 2 nodules. Higher scores indicated severe outcome. Treatment success was defined as an IGA score of 0 (clear) or 1 (almost clear), and at least a 2-step improvement (decrease) from Day 0/Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1","spread":null},{"groupId":"OG001","value":"43.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving IGA Treatment Success of at Least 2 Grades at Week 12","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. The Investigator assessed the global severity of rosacea using the IGA scale. The scale ranges from 0 (Clear): No inflammatory papules or pustules to 4 (Severe): Many inflammatory papules or pustules, and up to 2 nodules. Higher scores indicated severe outcome. Treatment success was defined as a 2-grade improvement (decrease) in score at Week 12 compared to Day 0/Baseline.\n\nHere, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percent Change From Day 0/Baseline in Inflammatory Lesion Count at Week 12","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. Lesion counts included the number of papules, pustules, and nodules.\n\nHere, overall number of participants analyzed signifies only the participants with available data that were analyzed for the outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.13","spread":"1.584"},{"groupId":"OG001","value":"56.52","spread":"2.133"}]}]}]},{"type":"SECONDARY","title":"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Counts at Week 4 and Week 8","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. Lesion counts included the number of papules, pustules, and nodules. The change from Baseline was calculated as the value at Baseline minus the post-Baseline value. Thus, a positive change reflects a reduction in lesion count.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.24","spread":"0.441"},{"groupId":"OG001","value":"8.62","spread":"0.608"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.59","spread":"0.445"},{"groupId":"OG001","value":"12.51","spread":"0.610"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving IGA Treatment Success at Week 4 and Week 8","description":"To determine the efficacy of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea. The Investigator assessed the global severity of rosacea using the IGA scale. The scale ranges from 0 (Clear): No inflammatory papules or pustules to 4 (Severe): Many inflammatory papules or pustules, and up to 2 nodules. Higher scores indicated severe outcome. Treatment success was defined as an IGA score of 0 (clear) or 1 (almost clear), and at least a 2-grade improvement (decrease) from Day 0/Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"To evaluate the tolerability and safety of topical minocycline foam applied once daily for 12 weeks. A treatment-emergent adverse events (TEAE) was defined as any AE with an onset date on or after the first application of study drug, and before to the last application of study drug plus 3 days, having been absent pre-treatment or worsening relative to the pre-treatment state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":494},"commonTop":["Upper respiratory tract infection"]}}}